Home
/
PALISADE BIO, INC.
/
Financials
/
Quarterly
PALISADE BIO, INC. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that PALISADE BIO, INC. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2017
Sep 30, 2017
$2.5K
Nov 8, 2017
Q2
2017
Jun 30, 2017
$2.5K
Aug 8, 2017
Q1
2017
Mar 31, 2017
$2.5K
May 10, 2017
Q3
2017
Sep 30, 2016
$2.5K
Nov 8, 2017
Q2
2017
Jun 30, 2016
$2.5K
Aug 8, 2017
Q1
2017
Mar 31, 2016
$2.5K
May 10, 2017
Q3
2016
Sep 30, 2015
$2.5K
Nov 8, 2016
Q2
2016
Jun 30, 2015
$2.5K
Aug 11, 2016
Q1
2016
Mar 31, 2015
$2.9K
May 9, 2016
Q3
2015
Sep 30, 2014
$5.0K
Nov 9, 2015
Q2
2015
Jun 30, 2014
$5.0K
Aug 10, 2015
Q1
2015
Mar 31, 2014
$4.2K
May 8, 2015
Q3
2014
Sep 30, 2013
$2.5K
Nov 7, 2014
Q2
2014
Jun 30, 2013
$2.5K
Aug 8, 2014
Q1
2014
Mar 31, 2013
$102.5K
May 12, 2014
Q3
2013
Sep 30, 2012
$170.8K
Nov 12, 2013
Q2
2013
Jun 30, 2012
$78.1K
Aug 8, 2013
Q1
2013
Mar 31, 2012
$156.3K
May 10, 2013
Q3
2012
Sep 30, 2011
$103.4K
Nov 9, 2012
Q2
2012
Jun 30, 2011
$0
Aug 9, 2012
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2024
Sep 30, 2024
$0
Nov 12, 2024
Q2
2024
Jun 30, 2024
$0
Aug 12, 2024
Q1
2024
Mar 31, 2024
$0
May 13, 2024
Q3
2024
Sep 30, 2023
$0
Nov 12, 2024
Q2
2024
Jun 30, 2023
$0
Aug 12, 2024
Q1
2024
Mar 31, 2023
$250.0K
May 13, 2024
Q3
2023
Sep 30, 2022
$0
Nov 9, 2023
Q2
2023
Jun 30, 2022
$0
Aug 10, 2023
Q1
2023
Mar 31, 2022
$0
May 11, 2023
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($2.87M)
Nov 10, 2025
Q2
2025
Jun 30, 2025
($2.78M)
Aug 11, 2025
Q1
2025
Mar 31, 2025
($2.23M)
May 12, 2025
Q3
2025
Sep 30, 2024
($3.49M)
Nov 10, 2025
Q2
2025
Jun 30, 2024
($4.08M)
Aug 11, 2025
Q1
2025
Mar 31, 2024
($3.53M)
May 12, 2025
Q3
2024
Sep 30, 2023
($3.60M)
Nov 12, 2024
Q2
2024
Jun 30, 2023
($3.39M)
Aug 12, 2024
Q1
2024
Mar 31, 2023
($2.34M)
May 13, 2024
Q3
2023
Sep 30, 2022
($3.99M)
Nov 9, 2023
Q2
2023
Jun 30, 2022
($2.34M)
Aug 10, 2023
Q1
2023
Mar 31, 2022
($4.21M)
May 11, 2023
Q3
2022
Sep 30, 2021
$8.09M
Nov 14, 2022
Q2
2022
Jun 30, 2021
($31.75M)
Aug 15, 2022
Q1
2022
Mar 31, 2021
($4.03M)
May 13, 2022
Q2
2021
Mar 31, 2021
($4.03M)
Aug 23, 2021
Q3
2021
Sep 30, 2020
($1.84M)
Nov 12, 2021
Q3
2020
Jun 30, 2020
($1.95M)
Nov 10, 2020
Q2
2021
Jun 30, 2020
($1.85M)
Aug 23, 2021
Q3
2020
Mar 31, 2020
($7.58M)
Nov 10, 2020
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($2.92M)
Nov 10, 2025
Q2
2025
Jun 30, 2025
($2.84M)
Aug 11, 2025
Q1
2025
Mar 31, 2025
($2.31M)
May 12, 2025
Q3
2025
Sep 30, 2024
($3.59M)
Nov 10, 2025
Q2
2025
Jun 30, 2024
($4.21M)
Aug 11, 2025
Q1
2025
Mar 31, 2024
($3.67M)
May 12, 2025
Q3
2024
Sep 30, 2023
($3.78M)
Nov 12, 2024
Q2
2024
Jun 30, 2023
($3.61M)
Aug 12, 2024
Q1
2024
Mar 31, 2023
($2.53M)
May 13, 2024
Q3
2023
Sep 30, 2022
($4.41M)
Nov 9, 2023
Q2
2023
Jun 30, 2022
($3.57M)
Aug 10, 2023
Q1
2023
Mar 31, 2022
($3.89M)
May 11, 2023
Q3
2022
Sep 30, 2021
($3.02M)
Nov 14, 2022
Q2
2022
Jun 30, 2021
($32.86M)
Aug 15, 2022
Q1
2022
Mar 31, 2021
($1.95M)
May 13, 2022
Q3
2021
Sep 30, 2020
($1.82M)
Nov 12, 2021
Q2
2021
Jun 30, 2020
($1.84M)
Aug 23, 2021
Q1
2021
Mar 31, 2020
($1.99M)
May 14, 2021
Q3
2020
Sep 30, 2019
($2.12M)
Nov 10, 2020
Q2
2020
Jun 30, 2019
($1.92M)
Aug 13, 2020